Contribute Try STAT+ Today

U.K. officials and Vertex Pharmaceuticals (VRTX) have finally put to rest a years-long battle over access to cystic fibrosis treatments, which came to symbolize the growing clash between cash-strapped governments and the pharmaceutical industry over the cost of medicines.

The four-year deal calls for government reimbursement for a new triple-combination therapy, which has the potential to treat 90% of cystic fibrosis patients. In turn, the drug maker has agreed to provide evidence for the medication, along with two older treatments, to a cost-effectiveness watchdog agency. The pricing and timetable for Vertex to submit the data were not disclosed.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.